This clinical trial is focused on studying the long-term safety and tolerability of a medication called cenerimod in adults with systemic lupus erythematosus (SLE). SLE is a chronic autoimmune disease where the body’s immune system mistakenly attacks healthy tissues, causing inflammation and damage to various parts of the body. The medication being tested, cenerimod, is taken as a film-coated tablet and is intended to be used alongside other ongoing treatments for SLE.

The purpose of this study is to evaluate how safe and well-tolerated cenerimod is when used over an extended period. Participants in the study will take a daily dose of 4 milligrams of cenerimod. The study is designed as an open-label, single-arm extension, meaning all participants will receive cenerimod, and there will be no comparison group receiving a placebo. The study will monitor participants for any side effects or adverse events that may occur during the treatment period.

Participants will be involved in the study for a maximum of 36 months, during which they will have regular check-ups to assess their health and any potential side effects from the medication. The study aims to gather information on the long-term effects of cenerimod to ensure it is a safe option for people living with systemic lupus erythematosus. This information will help healthcare providers make informed decisions about the use of cenerimod in treating SLE.